Plinabulin iv Solution in Prevention of TAC Induced Neutropenia
|
|
文献详情
编号/登记号：
注册时间：
研究开始时间：
研究结束时间：
项目类型：
本院角色：
多中心研究：
招募状态：
试验分期：
研究疾病/适应症：
研究类型：
研究单位：[1]BeyondSpring Pharmaceuticals Inc.[2]Harbin Medical University Cancer Hospital Harbin, Harbin, China, 150000[3]Fourth Hospital of Hebei Medical University Breast cancer department Shijiazhuang, Hebei, China, 500000河北医科大学第四医院[4]China-Japan Union Hospital of Jilin University Tumor department of Hematology Changchun, Jilin, China, 130000[5]Liaoning Cancer Hospital & Institute Shenyang, Shenyang, China, 110000[6]Dnipropetrovsk City Multifunctional Hospital #4 Oncology Department Dnepropetrovsk, Ukraine, 49102[7]Prykarpatskiy Regional Oncological Center Ivano-Frankivs'k, Ukraine, 76000[8]"V.T. Zaycev Institute of General and Urgent Surgery NAMS of Ukraine Dept. of Oncology Kharkiv, Ukraine, 61103[9]Public Institution Kryvyi Rih Oncology Center Krivoy Bereg, Ukraine, 50048[10]Kirovograd Regional Oncological Center Kropyvnytskyi, Ukraine, 25011[11]Odessa regional clinical hospital Thoracic Surgery Department Academician Zabolotnoho Odessa, Ukraine, 65025[12]Cancer Center of Guangzhou Medical University Breast Oncology Guangzhou, Guangzhou, China, 510000
研究目的：
The primary purpose of this study is to compare the duration of severe neutropenia (DSN) in patients treated with: Docetaxel, doxorubicin, and cyclophosphamide (TAC) + pegfilgrastim versus Docetaxel, doxorubicin, and cyclophosphamide (TAC) + monotheray plinabulin or combination plinabulin/pegfilgrastim Severe neutropenia is an absolute neutrophil count (ANC) <0.5 × 10^9/L. Docetaxel, doxorubicin, and cyclophosphamide (TAC) will be used as the chemotherapy in this study.
